BCM
UTHR icon

Boreal Capital Management’s United Therapeutics UTHR Stock Holding History

Boreal Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.7K Hold
40
– – 0.02% 249
2026
Q1 		$23.7K Hold
40
– – 0.02% 240
2025
Q4 		$19.5K Hold
40
– – 0.01% 273
2025
Q3 		$16.8K Buy
+40
New +$13.5K 0.01% 293

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Boreal Capital Management's UTHR Position: Q2 2026 in Review

Boreal Capital Management held its United Therapeutics (UTHR) position steady in Q2 2026 at 40 shares worth $21.7K. The position accounts for 0.02% of the portfolio, ranked #249.

Boreal Capital Management first reported a position in UTHR in Q3 2025 and has held it in 4 quarters since. The position peaked at $23.7K in Q1 2026. 878 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Boreal Capital Management held 40 shares of United Therapeutics worth $21.7K as of Q2 2026.
  • Boreal Capital Management left its United Therapeutics share count unchanged in Q2 2026.
  • United Therapeutics made up 0.02% of Boreal Capital Management's portfolio in Q2 2026, its #249 holding.
  • Boreal Capital Management first reported a position in United Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Boreal Capital Management's United Therapeutics position peaked at $23.7K in Q1 2026.
  • 878 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Boreal Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.